PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control Recruiting nowThis trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Curocell Inc. • Aim: Disease control
Last updated Jul 02, 2026 05:00 UTC
-
New CAR-T study aims to boost cancer treatment success
Disease control Recruiting nowThis study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track how the modified immune cells grow and last in the body after infusion. The goal is to see if this treatment is effective in real-world s…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New CAR T-Cell therapy SynKIR-310 enters first human trial for Tough-to-Treat lymphoma
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to target and attack cancer cells. The main go…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Experimental CAR-T therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new treatment called CLIC-2201 for people with B-cell cancers (like certain leukemias and lymphomas) that have come back or not responded to standard care. The treatment involves collecting a patient's own immune cells, modifying them to target a pr…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Gene therapy injection takes aim at Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Double-targeted cell therapy takes on hard-to-treat lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Engineered immune cells take on tough lymphoma
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells engineered to find and attack lymphoma cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial will check safety and h…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo aims to boost CAR T-Cell therapy for rare lymphoma
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard CAR T-cell therapy can improve outcomes for people with relapsed or refractory primary mediastinal B-cell lymphoma. About 35 participants will receive pembrolizumab before and afte…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New immune therapy shows promise for Tough-to-Treat lymphoma
Disease control Recruiting nowThis phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Double-Target CAR-T therapy takes on tough blood cancers
Disease control Recruiting nowThis phase 1/2 trial is testing a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to improve treatment for people with relapsed or refractory B-cell cancers like lymphoma and leukemia. The study will enroll up to 100 adults and eva…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin and some large B-cell lymphomas). Participants must be between 18 and 50 years old and have been in remission for 3 to 10 yea…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC